5116S-11: S0820 colon

SWOG 0820: A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon Cancer, Phase III

Type of Study
Cancer (Oncology) - Colon
Swedish Cancer Institute
Short Description

Purpose: The investigators hypothesize that the combination of eflornithine and sulindac will be effective in reducing a three-year event rate of adenomas and second primary colorectal cancers in patients previously treated for Stages 0 through III colon cancer

Open to Enrollment
Principal Investigator
Gary Goodman, M.D.
Eligibility Notes
  • History of Stage 0-III colon cancer with primary resection 1 year previously
  • Patients with rectosigmoid cancers eligible if no RT administered
  • One-year post-operative colonoscopy and CT scans of chest, abdomen & pelvis showing no evidence of disease
  • Low risk or moderate risk of cardiovascular events
  • At least 30 days from completion of prior adjuvant chemotherapy
  • Able to swallow oral medications
  • No history of colon resection > 40 cm
  • No mid-low rectal cancer
  • No recurrent or metastatic disease
More Info Link
Additional information about the study summary and eligibility criteria may be viewed on the U.S. National Institutes of Health (NIH) website.
(206) 215-3086